MGNX

MacroGenics Inc

Add to Watchlist

Advanced Chart

1.490

+0.02(1.361%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

1.490

Open

1.480

VWAP

1.48

Vol

28.75K

Mkt Cap

92.74M

Low

1.475

Amount

42.56K

EV/EBITDA(TTM)

Total Shares

62.63M

-61.40M

EV/OCF(TTM)

P/S(TTM)

0.60

MacroGenics, Inc. is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its suite of antibody-based technology platforms, which have applicability across broad therapeutic domains. It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its other product candidates are MGD024, retifanlimab, enoblituzumab, and vobramitamab duocarmazine. MGD024 is an investigational, next-generation, bispecific CD123 CD3 DART molecule designed to engage CD3 expressed on immune effector cells, such as T cells.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2025Q3

FY2025Q2

27.68M

+43.03%

23.31M

-78.94%

28.06M

+159.87%

Estimates Revision

The market is revising Upward the revenue expectations for MacroGenics, Inc. (MGNX) for FY2025, with the revenue forecasts being adjusted by 46.72% over the past three months. During the same period, the stock price has changed by -6.29%.

Revenue Estimates for FY2025

Revise Upward

+46.72%

In Past 3 Month

Stock Price

Go Down

-6.29%

In Past 3 Month

6 Analyst Rating

218.79% Upside

Wall Street analysts forecast MGNX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MGNX is 4.75 USD with a low forecast of 3.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

4 Hold

0 Sell

Moderate Buy

218.79% Upside

Current: 1.490

Low

3.00

Averages

4.75

High

8.00

218.79% Upside

Current: 1.490

Low

3.00

Averages

4.75

High

8.00

B. Riley

Neutral

downgrade

$5 -> $3

2025-05-20

Reason

B. Riley

Price Target

$5 -> $3

2025-05-20

downgrade

Neutral

Reason

B. Riley lowered the firm's price target on MacroGenics to $3 from $5 and keeps a Neutral rating on the shares. The company's key operational updates on a more focused oncology pipeline were noted on its earnings call, with management reaffirming guidance for disclosure of two key trial readouts in 2025, the analyst tells investors in a research note. B. Riley believes the end of selling pressure in the follow-up to the string of vobra duo-related disappointments may be nearing.

Barclays

Peter Lawson

Overweight

downgrade

$8 -> $3

2025-05-14

Reason

Barclays

Peter Lawson

Price Target

$8 -> $3

2025-05-14

downgrade

Overweight

Reason

Barclays analyst Peter Lawson lowered the firm's price target on MacroGenics to $3 from $8 and keeps an Overweight rating on the shares post the earnings report. The firm de-risked the model to reflect the current market environment.

Stifel

Hold

downgrade

$6 -> $5

2025-05-14

Reason

Stifel

Price Target

$6 -> $5

2025-05-14

downgrade

Hold

Reason

Stifel lowered the firm's price target on MacroGenics to $5 from $6 and keeps a Hold rating on the shares following earnings and a corporate update. An update from the fully-enrolled LORIKEET trial in chemotherapy-naive mCRPC patients due in the second half represents "a potentially important catalyst,' particularly given that the current valuation "doesn't imply any value here," says the analyst, whose updated model mostly reflects revised financing assumptions.

HC Wainwright & Co.

Robert Burns

Hold

Maintains

$4 → $2

2025-03-25

Reason

HC Wainwright & Co.

Robert Burns

Price Target

$4 → $2

2025-03-25

Maintains

Hold

Reason

JMP Securities

Silvan Tuerkcan

Buy

Hold

Downgrades

n/a

2024-11-07

Reason

JMP Securities

Silvan Tuerkcan

Price Target

n/a

2024-11-07

Downgrades

Buy

Hold

Reason

JMP Securities analyst Silvan Tuerkcan downgraded MacroGenics to Market Perform from Outperform without a price target. The company "is in a holding pattern" with respect to its pipeline, has paused all vobra duo development, including the lorigerlimab combo, and sold Margenza, the analyst tells investors in a research note. The firm cites the uncertain future of MacroGenics' B7-H3 franchise and lack of data and clarity on lorigerlimab and the DART programs for the downgrade. It views the shares as fairly valued currently.

HC Wainwright & Co.

Robert Burns

Hold

Reiterates

2024-11-06

Reason

HC Wainwright & Co.

Robert Burns

Price Target

2024-11-06

Reiterates

Hold

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for MacroGenics Inc (MGNX.O) is -0.75, compared to its 5-year average forward P/E of -4.07. For a more detailed relative valuation and DCF analysis to assess MacroGenics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-4.07

Current PE

-0.75

Overvalued PE

1.27

Undervalued PE

-9.40

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-3.58

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.25

Undervalued EV/EBITDA

-7.42

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

5.82

Current PS

1.15

Overvalued PS

10.51

Undervalued PS

1.14